| ABSTRACT Objective: To systematically evaluate the clinical efficacy and safety of reduning injection (RDN) in treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods:Randomized controlled trials (RCTs) regarding RDN in the treatment of AECOPD were searched in PubMed, Cochrane Library, SinoMed, Embase, CNKI, VIP and Wanfang database up to March 18th, 2017. Two researchers searched and selected the RCTs and extracted information independently. Quality of included RCTs was evaluated by the Cochrane Risk of Bias Assessment Tool, and then the required information was extracted and Meta analyzed by RevMan 5.3 and Stata 12.0 software. Results:A total of 12 RCTs with 992 patients were included. In the Meta analysis, RDN with routine western medicine (WM) could achieve a better effect than WM in respect of total effective rate (RR=1.19, 95%CI: 1.13 1.26, P<0.000 01). In addition, RDN could improve the FEV1/FVC (MD=8.89, 95%CI: 5.73 12.05, P<0.000 01), the FEV1% (MD=10.27, 95%CI: 5.11 15.44, P<0.000 1) and the level of C reactive protein (MD=-5.60, 95%CI: -9.94 -1.26, P=0.01). Three articles cleared that there was no ADRs/ADEs in the studies. Three studies reported 40 ADRs. Conclusion:RDN with WM is more effective in improving the total effective, the pulmonary function and the level of C reactive protein than WM to treat AECOPD. However, safety still need more evidence to support. |
